Increased sensitivity of the ryanodine receptor to halothane-induced oligomerization in malignant hyperthermia-susceptible human skeletal muscle

Journal of Applied Physiology

Volumn 96, Issue 1, 2004, Pages 11-18

  Glover, Louise ^a   Heffron, James J A ^b   Ohlendieck, Kay ^c  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b UNIVERSITY COLLEGE CORK   (Ireland)

^c NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

Calcium homeostasis; Excitation contraction coupling; Sarcoplasmic reticulum; Supramolecular complex; Triad

Indexed keywords

1,4 DIHYDROPYRIDINE RECEPTOR; ADENOSINE TRIPHOSPHATASE (CALCIUM); CALCIUM CHANNEL; CALCIUM ION; CALMODULIN; CALPHOBINDIN II; CALRETICULIN; CALSEQUESTRIN; HALOTHANE; JUNCTIN; RYANODINE RECEPTOR; SARCALUMENIN; UNCLASSIFIED DRUG;

ARTICLE; CALCIUM TRANSPORT; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE PREDISPOSITION; ENDOPLASMIC RETICULUM; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; MALIGNANT HYPERTHERMIA; METABOLISM; MUSCLE BIOPSY; MUSCLE CELL; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN GEL BLOT ANALYSIS; SARCOPLASMIC RETICULUM; SKELETAL MUSCLE;

ANESTHETICS, INHALATION; BIOPSY; CALCIUM; CALCIUM-TRANSPORTING ATPASES; CYTOPLASM; HALOTHANE; HUMANS; MALIGNANT HYPERTHERMIA; MUSCLE, SKELETAL; PROTEIN BINDING; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL; SARCOPLASMIC RETICULUM;

EID: 0347363490     PISSN: 87507587     EISSN: None     Source Type: Journal    
DOI: 10.1152/japplphysiol.00537.2003     Document Type: Article

References (49)

1. Alifimoff JK, Firestone LL, and Miller KW. Anaesthetic potencies of primary alkanols: implications for the molecular dimensions of the anaesthetic site. Br J Pharmacol 96: 9-16, 1989.
2. Ball SP and Johnson KJ. The genetics of malignant hyperthermia. J Med Genet 30: 89-93, 1993.
3. Berchtold MW, Brinkmeier H, and Muntener M. Calcium ion in skeletal muscle: its crucial role for muscle function, plasticity, and disease. Physiol Rev 80: 1215-1265, 2000.
4. Bradd SJ and Dunn MJ. Analysis of membrane proteins by western blotting and enhanced chemiluminescence. Methods Mol Biol 19: 211-218, 1993.
5. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
6. Brandt NR, Caswell AH, Wen SR, and Talvenheimo JA. Molecular interactions of the junctional foot protein and dihydropyridine receptor in skeletal muscle triads. J Membr Biol 113: 237-251, 1990.
7. 2+-ATPase. Biochem Biophys Res Commun 271: 770-776, 2000.
8. Butler-Browne GS, Erriksson PO, Laurent C, and Thornell LE. Adult human masseter muscle fibres express myosin isozymes characteristic of development. Muscle Nerve 11: 610-620, 1988.
9. Censier K, Urwyler A, Zorzato F, and Treves S. Intracellular calcium homeostasis in human primary muscle cells from malignant hyperthermia-susceptible and normal individuals. Effect of overexpression of recombinant wild-type and Arg163Cys mutated ryanodine receptors. J Clin Invest 101: 1233-1242, 1998.
10. 2+-stimulated ATPase activity. Anal Biochem 157: 375-380, 1986.
11. Dubois BW, Cherian SF, and Evers AS. Volatile anesthetics compete for common binding sites on bovine serum albumin: a 19F-NMR study. Proc Natl Acad Sci USA 90: 6478-6482, 1993.
12. Eckenhoff RG. Do specific or nonspecific interactions with proteins underlie inhalational anesthetic action? Mol Pharmacol 54: 610-615, 1998.
13. Eckenhoff RG and Johansson JS. Molecular interactions between inhaled anesthetics and proteins. Pharmacol Rev 49: 343-367, 1997.
14. Franks NP and Lieb WR. Molecular mechanisms of general anaesthesia. Nature 300: 487-493, 1982.
15. Franks NP and Lieb WR. Stereospecific effects of inhalational general anesthetic optical isomers on nerve ion channels. Science 254: 427-430, 1991.
16. Franks NP and Lieb WR. Molecular and cellular mechanisms of general anaesthesia. Nature 367: 607-614, 1994.
17. 2+-regulatory membrane proteins by halothane. Eur J Pharmacol 365: 91-102, 1999.
18. 2+-release channel: implications for malignant hyperthermia and the protein theory of anesthetic action. Naturwissenschaften 86: 584-587, 1999.
19. Froemming GR and Ohlendieck K. The role of ion-regulatory membrane proteins of excitation-contraction coupling and relaxation in inherited muscle diseases. Front Biosci 6: D65-D74, 2001.
20. Glover L, Quinn S, Ryan M, Pette D, and Ohlendieck K. Supramolecular calsequestrin complex. Eur J Biochem 269: 4607-4616, 2002.
21. Herrmann-Frank A, Richter M, and Lehmann-Horn F. 4-Chloro-m-cresol: a specific tool to distinguish between malignant hyperthermia-susceptible and normal muscle. Biochem Pharmacol 52: 149-155, 1996.
22. Janoff AS, Pringle MJ, and Miller KW. Correlation of general anesthetic potency with solubility in membranes. Biochim Biophys Acta 649: 125-128, 1981.
23. Jurkat-Rott K, Lerche H, and Lehmann-Horn F. Skeletal muscle channelopathies. J Neurol 249: 1493-1502, 2002.
24. Jurkat-Rott K, McCarthy T, and Lehmann-Horn F. Genetics and pathogenesis of malignant hyperthermia. Muscle Nerve 23: 4-17, 2000.
25. Karon BS, Autry JM, Shi Y, Garnett CE, Inesi G, Jones LR, Kutchai H, and Thomas DD. Different anesthetic sensitivities of skeletal and cardiac isoforms of the Ca-ATPase. Biochemistry 38: 9301-9307, 1999.
26. Karon BS, Geddis LM, Kutchai H, and Thomas DD. Anesthetics alter the physical and functional properties of the Ca-ATPase in cardiac sarcoplasmic reticulum. Biophys J 68: 936-945, 1995.
27. Karon BS and Thomas DD. Molecular mechanism of Ca-ATPase activation by halothane in sarcoplasmic reticulum. Biochemistry 32: 7503-7511, 1993.
28. Leong P and MacLennan DH. Complex interactions between skeletal muscle ryanodine receptor and dihydropyridine receptor proteins. Biochem Cell Biol 76: 681-694, 1998.
29. Lipnick RL. Hans Horst Meyer and the lipoid theory of narcosis. Trends Pharmacol Sci 10: 265-269, 1989.
30. Liu G and Pessah IN. Molecular interaction between ryanodine receptor and glycoprotein triadin involves redox cycling of functionally important hyperreactive sulfhydryls. J Biol Chem 269: 33028-33034, 1994.
31. 2+ release channels. Am J Med 104: 470-486, 1998.
32. 2+-ATPases? J Biol Chem 270: 28239-28245, 1995.
33. 2+ signalling and muscle disease. Eur J Biochem 267: 5291-5297, 2000.
34. Meissner G and Lu X. Dihydropyridine receptor-ryanodine receptor interactions in skeletal muscle excitation-contraction coupling. Biosci Rep 15: 399-408, 1995.
35. Melzer W and Dietze B. Malignant hyperthermia and excitation-contraction coupling. Acta Physiol Scand 171: 367-378, 2001.
36. Mickelson JR, Gallant EM, Litterer LA, Johnson KM, Rempel WE, and Louis CF. Abnormal sarcoplasmic reticulum ryanodine receptor in malignant hyperthermia. J Biol Chem 263: 9310-9315, 1988.
37. 2+ regulation defects. Physiol Rev 76: 537-592, 1996.
38. 2+-regulatory membrane proteins in normal, stimulated and pathological skeletal muscle (review). Int J Mol Med 1: 677-687, 1998.
39. +- regulating proteins. Curr Mol Med 2: 347-369, 2002.
40. Ording H, Brancadoro V, Cozzolino S, Ellis FR, Glauber V, Gonano EF, Halsall PJ, Hartung E, Heffron JJ, Heytens L, Kozak-Ribbens G, Kress H, Krivosic-Horber R, Lehmann-Horn F, Mortier W, Nivoche Y, Ranklev-Twetman E, Sigurdsson S, Snoeck M, Stieglitz P, Tegazzin V, Urwyler A, and Wappler F. In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: results of testing patients surviving fulminant MH and unrelated low-risk subjects. The European Malignant Hyperthermia Group. Acta Anaesthesiol Scand 41: 955-966, 1997.
41. O'Reilly C, Pette D, and Ohlendieck K. Increased expression of the nicotinic acetylcholine receptor in stimulated muscle. Biochem Biophys Res Commun 300: 585-591, 2003.
42. 2+ ions from human malignant hyperthermia-susceptible sarcoplasmic reticulum. Biochem Pharmacol 61: 1479-1485, 2001.
43. Pessah IN, Lynch C 3rd, and Gronert GA. Complex pharmacology of malignant hyperthermia. Anesthesiology 84: 1275-1279, 1996.
44. Pette D. The adaptive potential of skeletal muscle fibers. Can J Appl Physiol 27: 423-448, 2002.
45. Richter M, Schleithoff L, Deufel T, Lehmann-Horn F, and Herrmann-Frank A. Functional characterization of a distinct ryanodine receptor mutation in human malignant hyperthermia-susceptible muscle. J Biol Chem 272:5256-5260, 1997.
46. Taraschi TF, Lee YC, Janes N, and Rubin E. Anesthetic potency and conformational stability in membranes. Ann NY Acad Sci 625: 698-706, 1991.
47. 2+ release is altered by 15 calcium release channel (ryanodine receptor) mutations associated with malignant hyperthermia and/or central core disease. J Biol Chem 272: 26332-26339, 1997.
48. Trappe TA, Lindquist DM, and Carrithers JA. Muscle-specific atrophy of the quadriceps femoris with aging. J Appl Physiol 90: 2070-2074, 2001.
49. 2+ in the ryanodine receptor of human malignant hyperthermia. Am J Physiol Cell Physiol 261: C237-C245, 1991.